Overview
Elevance Health, Inc., based in the United States, operates within the healthcare sector, primarily focusing on improving lives and communities while streamlining the healthcare system. The company, formerly known as Anthem, Inc., offers a wide range of health care services that include commercial and government insurance covering both individuals and corporations. One of Elevance Health's key undertakings involves managing comprehensive and integrated health benefits through networks like Blue Cross Blue Shield in various states, which work to enhance access to quality care, improve overall mental, physical, and financial health, and ensure consumer satisfaction. Elevance Health also drives initiatives aimed at addressing social determinants of health, promoting wellness, and employing digital innovations to enhance healthcare delivery and efficiency.
Basic Stats
The Factor Analysis chart (below right) shows a view of Elevance Health, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 245.40 MM |
| Earnings Date | |
| EPS (TTM) | 18.63 |
| Dividend Yield | |
| Ex-Dividend Date | 2025-09-10 |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.06 |
| ROE | 0.14 |
| ROIC | 0.08 |
| CROIC | 0.01 |
| OCROIC | 0.20 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 8.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Elevance Health, Inc. is MX$7,000.84. The forecasts range from a low of MX$5,651.05 to a high of MX$11,004.57. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Elevance Health, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2025-01-06 | Truist Securities | Buy | Buy | Maintains |
| 2025-07-18 | Barclays | Overweight | Overweight | Maintains |
| 2025-07-18 | UBS | Buy | Buy | Maintains |
| 2024-08-19 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-07-22 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-07-18 | Barclays | Overweight | Overweight | Maintains |
| 2024-07-18 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-07-18 | B of A Securities | Buy | Neutral | Downgrade |
| 2024-07-15 | Truist Securities | Buy | Buy | Maintains |
| 2024-07-10 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-06-24 | Morgan Stanley | Overweight | Initiate | |
| 2024-06-12 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-06-11 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2024-06-04 | B of A Securities | Buy | Buy | Maintains |
| 2024-05-30 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-05-30 | Baird | Outperform | Initiate | |
| 2024-04-24 | Mizuho | Buy | Buy | Maintains |
| 2024-04-19 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-04-19 | UBS | Buy | Buy | Maintains |
| 2024-04-19 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-04-19 | Truist Securities | Buy | Buy | Reiterate |
| 2024-04-19 | Barclays | Overweight | Overweight | Maintains |
| 2024-04-19 | Jefferies | Buy | Buy | Maintains |
| 2024-04-10 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-04-08 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-04-04 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-03-06 | Barclays | Overweight | Initiate | |
| 2024-02-14 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2024-02-02 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-01-25 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-01-25 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-01-19 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-11-21 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-11-17 | JP Morgan | Overweight | Overweight | Maintains |
| 2023-10-19 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-10-19 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-09-14 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-07-25 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2023-07-24 | TD Cowen | Outperform | Outperform | Maintains |
| 2023-07-20 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2023-07-20 | RBC Capital | Outperform | Outperform | Reiterate |
| 2023-07-13 | UBS | Buy | Buy | Maintains |
| 2023-07-12 | Wolfe Research | Outperform | Peer Perform | Downgrade |
| 2023-07-07 | JP Morgan | Overweight | Overweight | Maintains |
| 2023-06-20 | Truist Securities | Buy | Buy | Maintains |
| 2023-04-27 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2023-04-24 | Wells Fargo | Overweight | Maintains | |
| 2023-04-21 | Loop Capital | Buy | Maintains | |
| 2023-04-21 | Cantor Fitzgerald | Overweight | Initiate | |
| 2023-04-20 | TD Cowen | Outperform | Maintains | |
| 2023-03-28 | RBC Capital | Sector Perform | Outperform | Upgrade |
| 2023-03-24 | Truist Securities | Buy | Maintains | |
| 2023-03-21 | Wells Fargo | Equal-Weight | Maintains | |
| 2023-03-08 | Deutsche Bank | Buy | Maintains | |
| 2023-02-23 | JP Morgan | Overweight | Maintains | |
| 2023-01-26 | RBC Capital | Sector Perform | Maintains | |
| 2023-01-26 | SVB Leerink | Outperform | Reiterate | |
| 2023-01-04 | Wells Fargo | Overweight | Maintains | |
| 2022-11-10 | Mizuho | Buy | Maintains | |
| 2022-10-21 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-10-21 | Deutsche Bank | Buy | Maintains | |
| 2022-09-09 | B of A Securities | Neutral | Buy | Upgrade |
| 2022-08-22 | SVB Leerink | Market Perform | Outperform | Upgrade |
| 2022-07-28 | Wells Fargo | Overweight | Maintains | |
| 2022-07-25 | Morgan Stanley | Equal-Weight | Maintains | |
| 2022-07-22 | SVB Leerink | Market Perform | Maintains | |
| 2024-09-20 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-07-23 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-07-22 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-07-19 | TD Cowen | Buy | Buy | Maintains |
| 2024-10-01 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-10-23 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2024-10-22 | Barclays | Overweight | Overweight | Maintains |
| 2024-10-21 | TD Cowen | Buy | Buy | Maintains |
| 2024-10-18 | Argus Research | Buy | Hold | Downgrade |
| 2024-10-18 | UBS | Buy | Buy | Maintains |
| 2024-10-18 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-10-18 | Truist Securities | Buy | Buy | Reiterate |
| 2024-10-18 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2024-09-10 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-09-05 | Stephens & Co. | Overweight | Overweight | Reiterate |
| 2025-04-11 | Truist Securities | Buy | Buy | Maintains |
| 2025-01-29 | Argus Research | Hold | Hold | Reiterate |
| 2025-01-28 | Wells Fargo | Overweight | Overweight | Maintains |
| 2024-11-05 | Mizuho | Outperform | Outperform | Maintains |
| 2024-11-04 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-07-25 | Baird | Neutral | Neutral | Maintains |
| 2025-04-15 | Baird | Outperform | Neutral | Downgrade |
| 2024-10-10 | Barclays | Overweight | Overweight | Maintains |
| 2025-01-24 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-01-24 | Barclays | Overweight | Overweight | Maintains |
| 2025-04-23 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-04-23 | Guggenheim | Buy | Buy | Reiterate |
| 2025-04-23 | RBC Capital | Outperform | Outperform | Reiterate |
| 2025-06-04 | RBC Capital | Outperform | Outperform | Reiterate |
| 2025-06-02 | Barclays | Overweight | Overweight | Maintains |
| 2025-08-15 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-04-09 | Guggenheim | Buy | Initiate | |
| 2025-04-09 | Mizuho | Outperform | Outperform | Maintains |
| 2025-07-18 | Guggenheim | Buy | Buy | Maintains |
| 2025-07-18 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2025-07-18 | Leerink Partners | Outperform | Market Perform | Downgrade |
| 2025-07-16 | Truist Securities | Buy | Buy | Maintains |
| 2025-09-04 | Barclays | Overweight | Overweight | Maintains |
| 2025-07-14 | UBS | Buy | Buy | Maintains |
| 2025-04-23 | Barclays | Overweight | Overweight | Maintains |
| 2025-06-09 | Truist Securities | Buy | Buy | Maintains |
| 2025-07-09 | Barclays | Overweight | Overweight | Maintains |
| 2025-07-21 | Argus Research | Buy | Hold | Downgrade |
| 2025-07-22 | Barclays | Overweight | Overweight | Maintains |
| 2025-07-15 | Wells Fargo | Overweight | Overweight | Maintains |
| 2025-09-05 | UBS | Buy | Buy | Maintains |
